GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (NAS:OVID) » Definitions » Beneish M-Score

Ovid Therapeutics (Ovid Therapeutics) Beneish M-Score : -3.28 (As of May. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.28 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Ovid Therapeutics's Beneish M-Score or its related term are showing as below:

OVID' s Beneish M-Score Range Over the Past 10 Years
Min: -23.07   Med: -3.28   Max: 11.22
Current: -3.28

During the past 9 years, the highest Beneish M-Score of Ovid Therapeutics was 11.22. The lowest was -23.07. And the median was -3.28.


Ovid Therapeutics Beneish M-Score Historical Data

The historical data trend for Ovid Therapeutics's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Beneish M-Score Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only - - 11.22 -23.07 -3.28

Ovid Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.07 -5.93 -3.88 -3.53 -3.28

Competitive Comparison of Ovid Therapeutics's Beneish M-Score

For the Biotechnology subindustry, Ovid Therapeutics's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Beneish M-Score falls into.



Ovid Therapeutics Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Ovid Therapeutics for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1+0.528 * 1+0.404 * 2.7269+0.892 * 0.261+0.115 * 0.8061
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 3.6725+4.679 * -0.059419-0.327 * 1.2298
=-3.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.00 Mil.
Revenue was 0.142 + 0.109 + 0.075 + 0.066 = $0.39 Mil.
Gross Profit was 0.142 + 0.109 + 0.075 + 0.066 = $0.39 Mil.
Total Current Assets was $109.60 Mil.
Total Assets was $144.03 Mil.
Property, Plant and Equipment(Net PPE) was $14.66 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.60 Mil.
Selling, General, & Admin. Expense(SGA) was $31.09 Mil.
Total Current Liabilities was $11.47 Mil.
Long-Term Debt & Capital Lease Obligation was $14.76 Mil.
Net Income was -15.322 + -11.252 + -12.408 + -13.356 = $-52.34 Mil.
Non Operating Income was -2.076 + 0.776 + 1.764 + 1.536 = $2.00 Mil.
Cash Flow from Operations was -11.912 + -10.051 + -11.705 + -12.112 = $-45.78 Mil.
Total Receivables was $0.00 Mil.
Revenue was 0.046 + 0.011 + 0 + 1.445 = $1.50 Mil.
Gross Profit was 0.046 + 0.011 + 0 + 1.445 = $1.50 Mil.
Total Current Assets was $131.38 Mil.
Total Assets was $155.27 Mil.
Property, Plant and Equipment(Net PPE) was $16.07 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.38 Mil.
Selling, General, & Admin. Expense(SGA) was $32.43 Mil.
Total Current Liabilities was $6.99 Mil.
Long-Term Debt & Capital Lease Obligation was $16.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0 / 0.392) / (0 / 1.502)
=0 / 0
=1

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1.502 / 1.502) / (0.392 / 0.392)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (109.598 + 14.663) / 144.027) / (1 - (131.381 + 16.071) / 155.266)
=0.137238 / 0.050327
=2.7269

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.392 / 1.502
=0.261

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.381 / (1.381 + 16.071)) / (1.596 / (1.596 + 14.663))
=0.079131 / 0.098161
=0.8061

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(31.085 / 0.392) / (32.432 / 1.502)
=79.298469 / 21.592543
=3.6725

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((14.756 + 11.474) / 144.027) / ((16.002 + 6.992) / 155.266)
=0.182119 / 0.148094
=1.2298

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-52.338 - 2 - -45.78) / 144.027
=-0.059419

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Ovid Therapeutics has a M-score of -3.28 suggests that the company is unlikely to be a manipulator.


Ovid Therapeutics Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics (Ovid Therapeutics) Business Description

Traded in Other Exchanges
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class or best-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Executives
Jason Tardio officer: Chief Commercial Officer 1460 BROADWAY, NEW YORK NY 10036
Takeda Pharmaceuticals U.s.a., Inc. 10 percent owner ONE TAKEDA PARKWAY, DEERFIELD IL 60015
Kevin Joseph Fitzgerald director C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Amit Rakhit officer: CMO and PMO C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Robert Michael Poole director 200 W. HIGHLAND DR., #303, SEATTLE WA 98119
Jeffrey A Rona officer: Chief Business Officer 500 PLAZA DRIVE, SECAUCUS NJ 07094
Jeremy M Levin director, 10 percent owner, officer: CEO
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Thomas Michael Perone officer: SVP, General Counsel 1460 BROADWAY, NEW YORK NY 10036
Karen Bernstein director C/O VITAE PHARMACEUTICLS, INC., 502 WEST OFFICE CENTER DRIVE, FORT WASHINGTON PA 19034
Millennium Pharmaceuticals Inc 10 percent owner 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Douglas E Williams director C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Ana Ward officer: SVP and General Counsel C/O OVID THERAPEUTICS INC., 1460 BROADWAY, SUITE 15044, NEW YORK NY 10036
Barbara Gayle Duncan director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Timothy Daly officer: VP, Finance & Corp. Controller 20 KINGSBRIDGE ROAD, PISCATAWAY NJ 08854